Evaxion Reports Three-Year Data for Melanoma Vaccine EVX-01
Evaxion reports three-year data for melanoma vaccine EVX-01, a personalized neoantigen candidate; the disclosure headline omits survival endpoints and cohort details.
Topic
Cancer Immunotherapy
Topic
Cancer Immunotherapy
Moderna and Merck Report Melanoma Vaccine Success in Large Trial
Moderna and Merck report their personalized mRNA melanoma vaccine succeeded in a large clinical trial, a milestone for mRNA cance…
Penn Tests mRNA Cancer Vaccine: What Dermatology Should Watch
Penn Medicine helped test a promising mRNA cancer vaccine, advancing a platform with direct implications for melanoma adjuvant th…